What are the guidelines for managing akathisia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management Guidelines for Akathisia

The first-line treatment for akathisia is lowering the dosage of the causative antipsychotic medication, switching to another antipsychotic with lower risk, or adding propranolol as a rescue medication. 1

Understanding Akathisia

Akathisia is a distressing neuropsychiatric syndrome characterized by:

  • Subjective feelings of inner restlessness and urge to move
  • Objective components including rocking while standing/sitting, lifting feet as if marching, and crossing/uncrossing legs
  • Significant distress that impacts treatment adherence and quality of life

Treatment Algorithm for Akathisia

Step 1: Modify Antipsychotic Treatment (First-line)

  • Reduce the dose of the causative antipsychotic if clinically feasible
  • Switch to an antipsychotic less likely to cause akathisia:
    • Consider quetiapine (initial dose: 12.5mg twice daily; maximum: 200mg twice daily) 2
    • Avoid typical antipsychotics and higher-potency atypicals when possible

Step 2: Add Rescue Medication (First-line if antipsychotic modification not possible)

  • Propranolol (non-selective beta-blocker): Most consistently effective treatment 3
    • Starting dose: 10-20mg twice or three times daily
    • May increase up to 80mg daily
    • Contraindications: asthma, diabetes, cardiovascular disease 1

Step 3: Alternative Rescue Medications (Second-line)

Use the "B-CALM" approach for alternatives 4:

  • B: Beta-blockers (propranolol, as above)
  • C: Clonazepam or other benzodiazepines
    • Lorazepam: 0.5-2mg as needed 2
    • Note: Regular use can lead to tolerance and dependence 2
  • A: Anticholinergics (if parkinsonian symptoms also present)
    • Benztropine: 1-2mg daily (maximum 6mg daily) 1
  • L: cLonidine (alpha-2 adrenergic agonist)
  • M: Mirtazapine
    • Low dose (7.5-15mg once daily) has shown compelling evidence 5

Step 4: Additional Options (Third-line)

  • Vitamin B6
  • Amantadine
  • Gabapentin or pregabalin
  • Trazodone (25-100mg) 1, 4

Special Considerations

Antipsychotic-Induced Akathisia

  • Second-generation (atypical) antipsychotics generally have lower risk than first-generation (typical) agents 2
  • Even atypicals like aripiprazole can cause akathisia 6
  • Monitor closely during the first few days after starting therapy or increasing dose 1

SSRI-Induced Akathisia

  • Similar management principles apply
  • Consider dose reduction or switching to another antidepressant

High-Risk Populations

  • Elderly patients (extremely sensitive to antipsychotic effects)
  • Very young patients
  • Males
  • Patients with previous history of tremors
  • Patients on polypharmacy
  • Patients on higher doses of antipsychotics 1

Monitoring

  • Use standardized assessment tools like the Barnes Akathisia Rating Scale
  • Regularly assess for abnormal movements during treatment
  • Monitor for orthostatic hypotension in patients with cardiovascular disease
  • Watch for paradoxical agitation with benzodiazepines (occurs in about 10% of patients) 2

Prognosis

  • Acute akathisia typically resolves upon treatment modification or with appropriate rescue medication
  • Tardive and chronic akathisia may persist after the causative agent is withdrawn and can be more resistant to treatment 6

Akathisia should be addressed promptly as it significantly impacts patient comfort, treatment adherence, and can potentially increase risk of suicidal ideation in severe cases 2, 7.

References

Guideline

Management of Psychosis in Parkinson's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.